Conjunctivitis Pharma Focus - Clinical Trial: Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis

Article

This clinical trial will determine moxifloxacin's efficacy for treating bacterial conjunctivitis.

Study Type: Interventional

Age/Gender Requirements: 1 month+ (male/female)

Sponsor: Alcon Research

Purpose: To evaluate the safety and efficacy of Moxifloxacin AF Ophthalmic Solution in comparison to Moxifloxacin AF Vehicle for treating bacterial conjunctivitis.

Click here to access this third-party resource.

Related Videos
Video 10 - "Future Treatment Landscape for COPD"
Video 9 - "Emerging Treatment Approaches in COPD"
A panel of 4 experts on HIV
A panel of 4 experts on HIV
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
© 2024 MJH Life Sciences

All rights reserved.